Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cells

• DOI: 10.1038/srep17523
• Publication Date: 2015-12-07T09:59:25Z
• Authors: Youlin Deng; Junhui Zhang; Zhongliang Wang; Zhengjian Yan; Min Qiao; Jixing Ye; Qiang Wei; Jing Wang; Xin Wang; Lianggong Zhao; Shun Lu; Shengli Tang; Maryam K. Mohammed; Hao Liu; Jiaming Fan; Fugui Zhang; Yulong Zou; Junyi Liao; Hongbo Qi; Rex C. Haydon; Hue H. Luu; Tong-Chuan He; Liangdan Tang
• Keywords: Monensin

Ovarian cancer is the most lethal gynecologic malignancy with an overall cure rate of merely 30%. Most patients experience recurrence within 12-24 months and die progressively chemotherapy-resistant disease. Thus, more effective anti-ovarian therapies are needed. Here, we investigate possibility repurposing antibiotic monensin as agent. We demonstrate that effectively inhibits cell proliferation, migration cycle progression, induces apoptosis human ovarian cells. Monensin suppresses multiple cancer-related pathways including Elk1/SRF, AP1, NFκB STAT, reduces EGFR expression in acts synergistically inhibitors oxaliplatin to inhibit proliferation induce Xenograft studies confirm tumor growth by suppressing through targeting signaling. Our results suggest may be repurposed agent although further preclinical clinical